Is Novo Nordisk’s Pipeline Deeper Than Its Valuation Implies?

Value investing is often about finding the divergence between popular narrative and underlying fundamentals. Right now, the dominant market consensus seems to be that Eli Lilly has decisively won the next-generation obesity and T2D pipeline war with retatrutide, leaving Novo Nordisk heavily reliant on aging semaglutide extensions. But when you look closely at the clinical data, Mr. Market might be getting this wrong. We need to talk about UBT251, the United Biotechnology partnership, and why Novo's long-term strategic positioning is significantly deeper than its current valuation implies. In phase 2 Chinese T2D patients showed up to 2.16% HbA1c reduction after 24 weeks and up to 9.8% weight loss. Earlier obesity data also showed up to 19.7% weight loss after 24 weeks. That matters because it starts to put Novo’s triple-agonist route into the same broader conversation as Lilly’s retatrutide. Not apples-to-apples. But the comparison is still interesting: Lilly’s recent phase 3 retatrutide data in T2D showed up to 2.0% A1C reduction and 16.8% weight loss at 40 weeks, while its earlier phase 2 obesity data showed up to 17.5% weight loss at 24 weeks (2.2% lower). So I’m not saying UBT251 has “caught” retatrutide, but I do think this makes it harder to argue that Novo only has semaglutide extensions left. Still early. Full data matters and the real test is whether UBT251 can reproduce this globally and at larger scale without glucagon-related trade-offs. But to me this does make Novo’s next-gen pipeline look deeper than the market currently gives it credit for. The United Biotechnology partnership is also interesting and could turn out to be strategically important for Novo’s long-term positioning in China. I wrote a deeper piece on Lilly vs Novo, pipeline, valuation and why I think the story is more balanced than the market narrative suggests. The link is attached to this post.